Ocular Therapeutix (OCUL) Preferred Stock Liabilities (2013 - 2014)
Ocular Therapeutix (OCUL) recorded quarterly Preferred Stock Liabilities of $74.4 million in Q2 2014, little changed quarter-over-quarter from $74.3 million in Q4 2013.
Ocular Therapeutix (OCUL) Preferred Stock Liabilities (2013 - 2014) Analysis & Trends
Ocular Therapeutix's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $74.4 million for Q2 2014.
- In Q2 2014, Preferred Stock Liabilities changed N/A year-over-year to $74.4 million; the TTM figure through Jun 2014 stood at $74.4 million (changed N/A YoY), while the FY2013 annual figure was $74.3 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $74.4 million for Q2 2014 at Ocular Therapeutix, roughly flat from $74.3 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $74.4 million in Q2 2014 to a low of $74.3 million in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ocular Therapeutix | 2.12 Bn | 2.12 Bn | 9.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2014 | 74.36 Mn |
| Dec 31, 2013 | 74.34 Mn |